Pregnant women and infants are at risk should they contract mpox but there are no approved vaccines for this population.

The registrational trial is expected to support the approval for Bavarian’s mpox/smallpox vaccine use in children 2-11 years ...

Bavarian Nordic gets $63 million US government order for small pox, mpox vaccine September 24, 2024 Future of Healthcategory Bavarian says mpox vaccine approved by EU regulator for adolescents ...

(Reuters) - An initial 899,000 vaccine doses have been allocated for 9 countries across Africa that have been hit hard by the ...

Last week African countries reported 2,532 new mpox cases, mostly in the Democratic Republic of the Congo (DRC) and Burundi, ...

The World Health Organization said on Monday it had approved Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17 years, an age group considered especially vulnerable to outbreaks of the ...

The World Health Organisation has given the Bavarian Nordic mpox vaccine the go ahead for use in adolescents aged 12 to 17, an age group which is viewed as especially vulnerable to the disease.

To safeguard against additional cases, either at home or while deployed, the Defense Health Agency and the services have made ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Here is how Bavarian Nordic (BVNRY) and Dare Bioscience, Inc. (DARE) have performed compared to their sector so far this year.

Results from this study could support an extension of the current approval of MVA-BN to include children from 2 years of age ...